Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 2373

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 4
Chunk 2373
---
 be recorded as stock-based
compensation expense over the remaining vesting term.

On October 1, 2024, the Company’s
Board of Directors granted directors, officers and employees options to purchase up to 47,780 shares of common stock for $10.00 per share.
The grants have various vesting conditions, including time-based and performance-based terms. These stock options expire on October 1,
2034.

F-28

Predecessor’s Stock
option activity for the period from December 31, 2023 through February 14, 2024 and the Company’s stock option activity for the
period from February 14, 2024 through December 31, 2024, was as follows:

             Weighted          Weighted   Average          Average   Remaining          Exercise   Contractual      Outstanding   Price Per   Life      Shares   Share   (in Years)   Balance, December 31, 2023 (Predecessor)   504   $418.92    6.86   Options cancelled (Predecessor)   (504)  $418.92        Balance, February 14, 2024 (Predecessor)   -   $-    -                     Balance, February 14, 2024 (Predecessor)   -   $-    -   Options granted (Successor)   98,180   $90.91    -   Options cancelled (Successor)   (33,232)  $146.12    -   Balance, December 31, 2024 (Successor)   64,948   $10.00    9.64   Options exercisable as of December 31, 2024   49,480   $10.00    9.68  

The intrinsic value of Predecessor
options exercised during the year ended December 31, 2023 was $9,458. No options were exercised in the Successor period from February
14, 2024 to December 31, 2024.

On March 25, 2024, the stockholders approved the CERo Therapeutics
Holdings, Inc. 202